PFE - AbbVie to acquire cancer drugmaker ImmunoGen for $10B cash
2023-11-30 07:42:10 ET
More on AbbVie, ImmunoGen, etc.
- AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade)
- Buy The Dip In AbbVie? Nope, Not This Time
- 4.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024
- AbbVie reports positive results from Phase 2 study for lung cancer drug
- AbbVie-Genmab lymphoma drug gets FDA breakthrough designation
For further details see:
AbbVie to acquire cancer drugmaker ImmunoGen for $10B cash